|
Aug 8
|
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
|
|
Aug 8
|
Personalis, Inc. (NASDAQ:PSNL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
|
Aug 8
|
Tempus Reports Second Quarter 2025 Results
|
|
Aug 5
|
Personalis: Q2 Earnings Snapshot
|
|
Aug 5
|
Personalis Reports Second Quarter 2025 Financial Results
|
|
Jul 28
|
Tempus AI (TEM) Secures FDA Clearance For ECG-Low EF Software
|
|
Jul 22
|
Personalis to Announce Second Quarter 2025 Financial Results
|
|
Jul 18
|
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 17
|
Tempus AI (TEM) Gains FDA Clearance for New Cardiovascular Risk Detection Software
|
|
Jul 17
|
Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer
|
|
Jul 3
|
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
|
|
Jun 18
|
The 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394%
|
|
Jun 17
|
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
|
|
Jun 2
|
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
|
|
Apr 11
|
With 33% stake, Personalis, Inc. (NASDAQ:PSNL) seems to have captured institutional investors' interest
|
|
Feb 13
|
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
|
|
Jan 20
|
Personalis (PSNL) Upgraded to Buy: Here's Why
|